HomeCompareADMS vs GBDC

ADMS vs GBDC: Dividend Comparison 2026

ADMS yields 24.33% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.68M in total portfolio value· pulled ahead in Year 3
10 years
ADMS
ADMS
● Live price
24.33%
Share price
$8.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$10,445.94
Full ADMS calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — ADMS vs GBDC

📍 GBDC pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADMSGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADMS + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADMS pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADMS
Annual income on $10K today (after 15% tax)
$2,068.13/yr
After 10yr DRIP, annual income (after tax)
$8,879.05/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,921,994.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADMS + GBDC for your $10,000?

ADMS: 50%GBDC: 50%
100% GBDC50/50100% ADMS
Portfolio after 10yr
$10.44M
Annual income
$8,199,854.67/yr
Blended yield
78.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ADMS
Analyst Ratings
6
Buy
7
Hold
2
Sell
Consensus: Hold
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADMS buys
0
GBDC buys
0
No recent congressional trades found for ADMS or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADMSGBDC
Forward yield24.33%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$94.9K$20.78M
Annual income after 10y$10,445.94$16,389,263.41
Total dividends collected$59.3K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: ADMS vs GBDC ($10,000, DRIP)

YearADMS PortfolioADMS Income/yrGBDC PortfolioGBDC Income/yrGap
1$13,133$2,433.09$12,490$1,790.28+$643.00ADMS
2$17,039$2,986.35$16,522$3,157.73+$517.00ADMS
3← crossover$21,852$3,621.00$23,578$5,898.68$1.7KGBDC
4$27,722$4,340.18$37,115$11,886.75$9.4KGBDC
5$34,809$5,145.80$66,136$26,423.57$31.3KGBDC
6$43,284$6,038.47$137,257$66,491.44$94.0KGBDC
7$53,331$7,017.47$341,734$194,868.54$288.4KGBDC
8$65,145$8,080.76$1,050,788$685,133.02$985.6KGBDC
9$78,930$9,225.06$4,099,314$2,974,971.01$4.02MGBDC
10$94,901$10,445.94$20,775,530$16,389,263.41$20.68MGBDC

ADMS vs GBDC: Complete Analysis 2026

ADMSStock

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Full ADMS Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ADMS vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADMS vs SCHDADMS vs JEPIADMS vs OADMS vs KOADMS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.